Physician profile
Emad Atta
NPI 1851587505
$361.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $88.92 · 2021: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $61.87 | 2019-2020 | |
| Exeltis, USA INC. | $44.39 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.60 | 2019 | |
| Hologic Sales and Service, LLC | $33.21 | 2019-2021 | |
| Lupin INC. | $24.63 | 2019 | |
| Abbvie INC. | $22.04 | 2019 | |
| Therapeuticsmd, INC. | $21.23 | 2021 | |
| Eisai INC. | $21.13 | 2019 | |
| Merck Sharp & Dohme LLC | $20.31 | 2021 | |
| Becton, Dickinson and Company | $20.20 | 2021 | |
| Coloplast Corp | $13.80 | 2019 | |
| Sage Therapeutics, LLC | $13.79 | 2019 | |
| Myovant Sciences INC. | $13.76 | 2021 | |
| Covidien Lp | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Atta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.